FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Bibby

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Procedures

Anatomy

Concepts & Ideas

Drug Dose Response Relationship

Physiology

Cell Divisions

Co-author Network

Publications

TOP 3
Jennifer M Atkinson; Robert A Falconer; Dylan R Edwards; Caroline J Pennington; Catherine S Siller; Steven D Shnyder; Michael C Bibby; Laurence H Patterson; Paul M Loadman; Jason H Gill
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.
Ekatherine M Prokopiou; Patricia A Cooper; George R Pettit; Michael C Bibby; Steven D Shnyder
Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.
Steven D Shnyder; Patricia A Cooper; Nicola J Millington; Jason H Gill; Michael C Bibby
Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Bibby (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Jennifer M Atkinson; Robert A Falconer; Dylan R Edwards; Caroline J Pennington; Catherine S Siller; Steven D Shnyder; Michael C Bibby; Laurence H Patterson; Paul M Loadman; Jason H Gill
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.
Cancer research 2010;70(17):6902-12.
2010: Ekatherine M Prokopiou; Patricia A Cooper; George R Pettit; Michael C Bibby; Steven D Shnyder
Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.
Molecular medicine reports 2010;3(2):309-13.
2008: Steven D Shnyder; Patricia A Cooper; Nicola J Millington; Jason H Gill; Michael C Bibby
Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model.
Journal of natural products 2008;71(3):321-4.
2007: Steven D Shnyder; Patricia A Cooper; Nicola J Millington; George R Pettit; Michael C Bibby
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.
International journal of oncology 2007;31(2):353-60.
2006: Marie Suggitt; Patricia A Cooper; Steven D Shnyder; Michael C Bibby
The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
International journal of oncology 2006;29(6):1493-9.
2006: Steven D Shnyder; Patricia A Cooper; Andy Scally; Michael C Bibby
Reducing the cost of screening novel agents using the hollow fibre assay.
Anticancer research 2006;26(3A):2049-52.
2006: Dimitrios Pletsas; Richard T Wheelhouse; Vassiliki Pletsa; Anna Nicolaou; Terence C Jenkins; Michael C Bibby; Soterios A Kyrtopoulos
Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.
European journal of medicinal chemistry 2006;41(3):330-9.
2005: Jurjees Hasan; Steven D Shnyder; Andrew R Clamp; Alan T McGown; Roy Bicknell; Marco Presta; Michael C Bibby; John A Double; Steven Craig; David Leeming; Kenneth Stevenson; John T Gallagher; Gordon C Jayson
Heparin octasaccharides inhibit angiogenesis in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8172-9.
2005: Steven D Shnyder; Jurjees Hasan; Patricia A Cooper; E Pilarinou; E Jubb; Gordon C Jayson; Michael C Bibby
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
Anticancer research 2005;25(3B):1889-94.
2005: Jill M Seargent; Paul M Loadman; Sandie W Martin; Brian Naylor; Michael C Bibby; Jason H Gill
Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.
Urology 2005;65(4):815-20.
2005: Marie Suggitt; Michael C Bibby
50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):971-81.
2004: Chee-Onn Leong; Marie Suggitt; David J Swaine; Michael C Bibby; Malcolm F G Stevens; Tracey D Bradshaw
In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
Molecular cancer therapeutics 2004;3(12):1565-75.
2004: Alison Blackburn; Michael C Bibby; Mark Lucock; Anna Nicolaou
Temporal evaluation of methionine synthase and related metabolites in the MAC15A mouse adenocarcinoma animal model.
International journal of cancer. Journal international du cancer 2004;112(4):577-84.
2004: Jason H Gill; Ian G Kirwan; Jill M Seargent; Sandie W Martin; Sidiq Tijani; Vladimir A Anikin; Alan J Mearns; Michael C Bibby; Alan Anthoney; Paul M Loadman
MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.
Neoplasia (New York, N.Y.) 2004;6(6):777-85.
2004: Simon S Jensen; Thomas L Andresen; Jesper Davidsen; Pernille Høyrup; Steven D Shnyder; Michael C Bibby; Jason H Gill; Kent Jørgensen
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Molecular cancer therapeutics 2004;3(11):1451-8.
2004: Marie Suggitt; David J Swaine; George R Pettit; Michael C Bibby
Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6677-85.
2004: Nagwa A Shoeib; Michael C Bibby; Gerald Blunden; Peter A Linley; David J Swaine; Richard T Wheelhouse; Colin W Wright
In-vitro cytotoxic activities of the major bromophenols of the red alga Polysiphonia lanosa and some novel synthetic isomers.
Journal of natural products 2004;67(9):1445-9.
2004: Shafii Khamis; Michael C Bibby; John E Brown; Patricia A Cooper; Ian Scowen; Colin W Wright
Phytochemistry and preliminary biological evaluation of Cyathostemma argenteum, a malaysian plant used traditionally for the treatment of breast cancer.
Phytotherapy research : PTR 2004;18(7):507-10.
2004: Michael C Bibby
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.
European journal of cancer (Oxford, England : 1990) 2004;40(6):852-7.
2004: Athanasia Varvaresou; Kritonas Iakovou; Evagelos Gikas; Iduna Fichtner; Heinz-Herbert Fiebig; Lloyd R Kelland; John A Double; Michael C Bibby; HR Hendriks
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Anticancer research 2004;24(2B):907-19.
2004: Ian G Kirwan; Paul M Loadman; David J Swaine; D Alan Anthoney; George R Pettit; John W Lippert; Steven D Shnyder; Patricia A Cooper; Michael C Bibby
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1446-53.
2004: Jurjees Hasan; Steven D Shnyder; Michael C Bibby; John A Double; R Bicknel; Gordon C Jayson
Quantitative angiogenesis assays in vivo--a review.
Angiogenesis 2004;7(1):1-16.
2004: D Alwyn Dart; Steven M Picksley; Patricia A Cooper; John A Double; Michael C Bibby
The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment.
International journal of oncology 2004;24(1):115-25.
2003: Steven D Shnyder; Patricia A Cooper; N Gyselinck; B T Hill; John A Double; Michael C Bibby
Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model.
Anticancer research 2003;23(6C):4815-20.
2003: Michael C Bibby
An introduction to telomeres and telomerase.
Molecular biotechnology 2003;24(3):295-301.
2003: Paul Gibson; Jason H Gill; Parveen A Khan; Jill M Seargent; Sandie W Martin; Philip A Batman; John Griffith; Christopher Bradley; John A Double; Michael C Bibby; Paul M Loadman
Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development.
Molecular cancer therapeutics 2003;2(6):527-34.
2003: Steven D Shnyder; Patricia A Cooper; George R Pettit; John W Lippert; Michael C Bibby
Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.
Anticancer research 2003;23(2B):1619-23.
2003: Chee-Onn Leong; Margaret Gaskell; E A Martin; RT Heydon; Peter B Farmer; Michael C Bibby; Patricia A Cooper; John A Double; Tracey D Bradshaw; Malcolm F G Stevens
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
British journal of cancer 2003;88(3):470-7.
2003: Marie Suggitt; J Fearnley; David J Swaine; Milène Volpato; Roger M Phillips; Michael C Bibby; Paul M Loadman; Diana Anderson
Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action.
Teratogenesis, carcinogenesis, and mutagenesis 2003;Suppl 2():13-29.
2002: SE Holwell; Patricia A Cooper; M J Thompson; George R Pettit; L W Lippert; Sandie W Martin; Michael C Bibby
Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Anticancer research 2002;22(6C):3933-40.
2002: Paul M Loadman; Michael C Bibby; Roger M Phillips
Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.
British journal of pharmacology 2002;137(5):701-9.
2002: Saghir Akhtar; Debbie Dunnion; David R Poyner; John Ackroyd; Michael C Bibby; John A Double
Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity.
Biochemical pharmacology 2002;63(12):2187-95.
2002: SE Holwell; Patricia A Cooper; Konstantina Grosios; John W Lippert; George R Pettit; Steven D Shnyder; Michael C Bibby
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Anticancer research 2002;22(2A):707-11.
2002: Tracey D Bradshaw; Michael C Bibby; John A Double; Iduna Fichtner; Patricia A Cooper; Michael C Alley; Susan Donohue; Sherman F Stinson; Joseph E Tomaszewjski; Edward A Sausville; Malcolm F G Stevens
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Molecular cancer therapeutics 2002;1(4):239-46.
2002: Michael C Bibby
Introduction to telomeres and telomerase.
Methods in molecular biology (Clifton, N.J.) 2002;191():1-12.
2002: K M Nicholson; Roger M Phillips; Steven D Shnyder; Michael C Bibby
In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine.
European journal of cancer (Oxford, England : 1990) 2002;38(1):194-204.
2001: Paul M Loadman; David J Swaine; Michael C Bibby; Kevin J Welham; Laurence H Patterson
A preclinical pharmacokinetic study of the bioreductive drug AQ4N.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):422-6.
2001: SE Holwell; B T Hill; Michael C Bibby
Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model.
British journal of cancer 2001;84(2):290-5.
2000: Saghir Akhtar; M D Hughes; A Khan; Michael C Bibby; M Hussain; Q Nawaz; John A Double; P Sayyed
The delivery of antisense therapeutics.
Advanced drug delivery reviews 2000;44(1):3-21.
2000: M J Thompson; S Abdul-Rahman; TG Baker; Joseph Rafferty; Geoffrey P Margison; Michael C Bibby
Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents.
Journal of reproduction and fertility 2000;119(2):339-46.
2000: David J Swaine; Paul M Loadman; Michael C Bibby; M A Graham; Laurence H Patterson
High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(2):239-45.
2000: Laurence H Patterson; Stephanie R McKeown; Ketan Chatrabhuj Ruparelia; John A Double; Michael C Bibby; S Cole; Ian J Stratford
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
British journal of cancer 2000;82(12):1984-90.
2000: Paul M Loadman; Roger M Phillips; L E Lim; Michael C Bibby
Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Biochemical pharmacology 2000;59(7):831-7.
2000: Konstantina Grosios; Paul M Loadman; David J Swaine; George R Pettit; Michael C Bibby
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.
Anticancer research 2000;20(1A):229-33.
1999: Konstantina Grosios; SE Holwell; A T McGown; George R Pettit; Michael C Bibby
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
British journal of cancer 1999;81(8):1318-27.
1999: Paul M Loadman; Michael C Bibby; John A Double; W M Al-Shakhaa; R Duncan
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3682-8.
1999: Angelika Burger; T C Jenkins; John A Double; Michael C Bibby
Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311.
British journal of cancer 1999;81(2):367-75.
1999: Michael C Bibby
Making the most of rodent tumour systems in cancer drug discovery.
British journal of cancer 1999;79(11-12):1633-40.
1999: Michael C Bibby; M J Thompson; Joseph Rafferty; Geoffrey P Margison; R Stanley McElhinney
Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice.
British journal of cancer 1999;79(9-10):1332-9.
1999: CR Calabrese; Paul M Loadman; L S Lim; Michael C Bibby; John A Double; J E Brown; J H Lamb
In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(2):240-5.
1998: Roger M Phillips; J Pearce; Paul M Loadman; Michael C Bibby; Patricia A Cooper; David J Swaine; John A Double
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs.
Cancer research 1998;58(23):5263-6.
1998: M J Thompson; R Slack; John A Double; Michael C Bibby
Microsatellite instability, chemosensitivity and mutant frequency in a series of 1,2-dimethylhydrazine induced murine colon adenocarcinoma models.
International journal of oncology 1998;13(3):531-6.
1998: CR Calabrese; Michael C Bibby; John A Double; Paul M Loadman
Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice.
Cancer chemotherapy and pharmacology 1998;42(5):379-85.
1997: K M Nicholson; Michael C Bibby; Roger M Phillips
Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1291-8.
1997: O Safa; Susan M Parkin; Michael C Bibby
IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.
Biochemical Society transactions 1997;25(2):265S.
1997: R J Hambly; John A Double; M J Thompson; Michael C Bibby
Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice.
Breast cancer research and treatment 1997;43(3):247-58.
1997: S Patel; Susan M Parkin; Michael C Bibby
The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells.
Anticancer research 1997;17(1A):141-50.
1997: O Safa; Susan M Parkin; A M Matthew; Michael C Bibby
Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts.
Anticancer research 1997;17(1A):37-43.
1997: Angelika Burger; Michael C Bibby; John A Double
Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy.
British journal of cancer 1997;75(4):516-22.
1996: Angelika Burger; John A Double; J Konopa; Michael C Bibby
Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.
British journal of cancer 1996;74(9):1369-74.
1996: A J Moore; Wayne D Beazley; Michael C Bibby; D A Devine
Antimicrobial activity of cecropins.
The Journal of antimicrobial chemotherapy 1996;37(6):1077-89.
1996: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; M Radacic; P Dumont
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
Journal of medicinal chemistry 1996;39(7):1403-12.
1996: Paul M Loadman; A M Matthew; J E McCormick; R Stanley McElhinney; Michael C Bibby
Pharmacokinetics and anti-tumour activity of B.4152, a reactive molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, and its uracil analogue.
Anti-cancer drug design 1996;11(2):117-28.
1996: M J Thompson; S Abdhul-Rahmann; T G Baker; Michael C Bibby
Potentiation of testicular cytotoxicity by the alkyltransferase inhibitor O6 benzylguanine and the 5-fluorouracil/N-(2-chloroethyl)-N-nitrosourea molecular combination, B.4152.
Reproductive toxicology (Elmsford, N.Y.) 1996;10(1):71-7.
1996: John R Masters; B J McDermott; Stephen J Harland; Michael C Bibby; Paul M Loadman
ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.
Cancer chemotherapy and pharmacology 1996;38(1):59-64.
1995: A J Moore; Paul M Loadman; D A Devine; Michael C Bibby
Extraction of the synthetic lytic peptide, cecropin B, from biological fluid and analysis using reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;672(2):225-31.
1995: S E Ebrahimi; Michael C Bibby; K R Fox; Kenneth T Douglas
Synthesis, DNA binding, footprinting and in vitro antitumour studies of a meta-hydroxy analogue of Hoechst 33258.
Anti-cancer drug design 1995;10(6):463-79.
1995: A L Laws; A M Matthew; John A Double; Michael C Bibby
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
British journal of cancer 1995;71(6):1204-9.
1995: J Collard; A M Matthew; John A Double; Michael C Bibby
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
British journal of cancer 1995;71(6):1199-203.
1995: S E Cowen; Michael C Bibby; John A Double
Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies.
Acta oncologica (Stockholm, Sweden) 1995;34(3):357-60.
1994: A J Moore; D A Devine; Michael C Bibby
Preliminary experimental anticancer activity of cecropins.
Peptide research 1994;7(5):265-9.
1994: Paul M Loadman; Michael C Bibby
Pharmacokinetic drug interactions with anticancer drugs.
Clinical pharmacokinetics 1994;26(6):486-500.
1994: S R Hill; Michael C Bibby
5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice.
Cancer chemotherapy and pharmacology 1994;34(1):57-62.
1993: Michael C Bibby; John A Double; J E McCormick; R Stanley McElhinney; M Radacic; G Pratesi; P Dumont
Nucleoside analogues. 13. The effect on anti-tumour activity of varying the uracil 5-substituent and the point of attachment (N1 or N3) of the uracil moiety in seco-nucleoside nitrosoureas.
Anti-cancer drug design 1993;8(2):115-28.
1993: A M Matthew; Roger M Phillips; Paul M Loadman; Michael C Bibby
Pre-clinical evaluation of a novel chloroethylating agent, Clomesone.
British journal of cancer 1993;67(3):441-6.
1993: Michael C Bibby; N R Sleigh; Paul M Loadman; John A Double
Potentiation of EO9 anti-tumour activity by hydralazine.
European journal of cancer (Oxford, England : 1990) 1993;29A(7):1033-5.
1993: A M Matthew; Michael C Bibby; G Eisenbrand
Pharmacokinetic studies of chloroethylnitrosocarbamoyl-amino acid derivatives in vivo and in vitro.
Anticancer research 1993;13(1):81-6.
1992: S R Hill; L A Pollard; Michael C Bibby
Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma.
Anticancer research 1992;12(6B):2169-75.
1992: P K Quinn; Michael C Bibby; J A Cox; S M Crawford
The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours.
British journal of cancer 1992;66(2):323-30.
1992: T Z Woldemariam; AF Fell; P A Linley; Michael C Bibby; Roger M Phillips
Evaluation of the anti-tumour action and acute toxicity of kosins from Hagenia abyssinica.
Journal of pharmaceutical and biomedical analysis 1992;10(8):555-60.
1992: Paul M Loadman; Michael C Bibby; John A Double; R Stanley McElhinney
Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.
Investigational new drugs 1992;10(3):149-58.
1992: A M Matthew; Michael C Bibby; John A Double
Anti-tumour activity and bone marrow toxicity of chloroethylnitrosocarbamoyl-amino acid derivatives.
Anticancer research 1992;12(2):361-5.
1992: Roger M Phillips; P B Hulbert; Michael C Bibby; N R Sleigh; John A Double
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.
British journal of cancer 1992;65(3):359-64.
1992: Michael C Bibby; Paul M Loadman; A F al-Ghabban; John A Double
Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
British journal of cancer 1992;65(3):347-50.
1992: O Aghil; Michael C Bibby; S J Carrington; J Double; Kenneth T Douglas; Roger M Phillips; T K Shing
Synthesis and cytotoxicity of shikimate analogues. Structure:activity studies based on 1-crotonyloxymethyl-3R,4R,5R-trihydroxycyclohex-2-enone.
Anti-cancer drug design 1992;7(1):67-82.
1991: Michael C Bibby; Roger M Phillips; John A Double
The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours.
British journal of cancer 1991;63(4):541-5.
1991: Roger M Phillips; Michael C Bibby; John A Double; Paul M Loadman
The relationship between the in vitro chemosensitivity of tumor cells and tumor response in vivo in an experimental tumor model.
International journal of cell cloning 1991;9(2):144-54.
1991: Michael C Bibby; Roger M Phillips; John A Double; G Pratesi
Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.
British journal of cancer 1991;63(1):57-62.
1990: R M Phillips; Michael C Bibby; John A Double
A critical appraisal of the predictive value of in vitro chemosensitivity assays.
Journal of the National Cancer Institute 1990;82(18):1457-68.
1990: John R Masters; B J McDermott; W E Jenkins; E Fenwick; P J Shah; A R Mundy; Paul M Loadman; Michael C Bibby
ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.
Cancer chemotherapy and pharmacology 1990;25(4):267-73.
1989: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; G Atassi; P Dumont; G Pratesi; M Radacic
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Anti-cancer drug design 1989;4(3):191-207.
1989: John A Double; Michael C Bibby
Therapeutic index: a vital component in selection of anticancer agents for clinical trial.
Journal of the National Cancer Institute 1989;81(13):988-94.
1989: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; G Atassi; P Dumont; G Pratesi; M Radacic
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
Anti-cancer drug design 1989;4(1):1-20.
1989: R Stanley McElhinney; J E McCormick; Michael C Bibby; John A Double; G Atassi; P Dumont; G Pratesi; M Radacic
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
Anti-cancer drug design 1989;3(4):255-69.
1989: Michael C Bibby; John A Double; Paul M Loadman; C V Duke
Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.
Journal of the National Cancer Institute 1989;81(3):216-20.
1989: Michael C Bibby; Roger M Phillips; John A Double
Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512).
Cancer chemotherapy and pharmacology 1989;24(2):87-94.
1988: Michael C Bibby; John A Double; Paul M Loadman
Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
British journal of cancer 1988;58(3):341-4.
1988: Roger M Phillips; Michael C Bibby; John A Double
In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation.
European journal of cancer & clinical oncology 1988;24(8):1365-71.
1988: Michael C Bibby; John A Double; C M Morris
Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.
European journal of cancer & clinical oncology 1988;24(8):1361-4.
1988: John A Double; Michael C Bibby; Paul M Loadman; J C Bloomer
Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.
European journal of cancer & clinical oncology 1988;24(8):1355-60.
1988: Michael C Bibby; John A Double; I A Wahed; N Hirbawi; T G Baker
The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
British journal of cancer 1988;58(2):139-43.
1988: Michael C Bibby; John A Double; Roger M Phillips; Paul M Loadman; J A Gummer
Experimental anti-tumor effects of flavone acetic acid (LM975).
Progress in clinical and biological research 1988;280():243-6.
1988: Roger M Phillips; Michael C Bibby; John A Double
Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours.
Cancer chemotherapy and pharmacology 1988;21(2):168-72.
1987: Michael C Bibby; John A Double; Roger M Phillips; Paul M Loadman
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).
British journal of cancer 1987;55(2):159-63.
1987: I Wahed; Michael C Bibby; T G Baker
Comparative effects of mitozolomide (M & B 39125, NSC 353451) and a series of standard anticancer drugs on mouse testis.
Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement 1987;11():277-80.
1987: I Wahed; Michael C Bibby; T G Baker
Quantitative methods for assessing the effects of some anticancer drugs on mouse spermatogenesis.
Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement 1987;11():273-6.
1987: Michael C Bibby; B J McDermott; John A Double; Roger M Phillips; Paul M Loadman; L Burgess
Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours.
Cancer chemotherapy and pharmacology 1987;20(3):203-6.
1986: John A Double; Michael C Bibby; Paul M Loadman
Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.
British journal of cancer 1986;54(4):595-600.
1986: John A Double; Michael C Bibby; J E McCormick; R Stanley McElhinney
Nucleoside analogues. 5. Molecular combination of anti-cancer drugs: activity of 5-fluorouracil/nitrosourea combinations against mouse colon tumours.
Anti-cancer drug design 1986;1(2):133-9.
1985: B J McDermott; John A Double; Michael C Bibby; D E Wilman; Paul M Loadman; R L Turner
Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens.
Journal of chromatography 1985;338(2):335-45.